News
Santhera submits marketing authorisation application for vamorolone
Santhera has announced that the company has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for vamorolone. The therapy is used for the treatment of Duchenne muscular dystrophy (DMD).